VVP
BMRN icon

Venture Visionary Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Venture Visionary Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-59
Closed -$4.89K – 588
2022
Q2 		$4.89K Buy
+59
New +$4.7K ﹤0.01% 1407

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Venture Visionary Partners's BMRN Position: Q3 2022 in Review

Venture Visionary Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 59 shares — an estimated $4.89K sold.

Venture Visionary Partners first reported a position in BMRN in Q2 2022 and held it in 1 quarter. The position peaked at $4.89K in Q2 2022. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

  • Venture Visionary Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 59 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $4.89K.
  • Venture Visionary Partners first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's BioMarin Pharmaceuticals position peaked at $4.89K in Q2 2022.
  • 551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.